GENETIC VARIANTS OF FUNCTIONING OF THE KEY PATHOGENETIC MECHANISMS IN PATIENTS WITH MYOCARDIAL INFARCTION AND ACUTE CARDIORENAL SYNDROME
https://doi.org/10.18705/2311-4495-2017-4-6-6-12
Abstract
The aim of this study was to evaluate, depending upon presence, the impact of genes polymorphism Leu-28Pro APOE, G681A CYP2C19, Trp212Тer CYP2C19, Val174Ala SLCO1B1, C786T NOS3 on the clinical course of myocardial infarction (MI ) in patients with associated acute kidney injury (AKI) in hospital. The study included 86 patients treated in SPb Research Institute of Emergency Care. I. I. Dzhanelidze in 2016 about IM. All patients were divided into 2 groups. The first (I) included 34 patients with MI and AKI. The second one — 52 patients with MI without AKI. All patients were taken venous blood, to detect polymorphic genes variants. The method was based upon the analysis of genomic human DNA, isolated from blood leukocytes by polymerase chain reaction. We compared the data of gene analysis and clinical presentation between groups. The representativeness and significance of differences between parameters in the samples evaluated using the nonparametric angular Fischer criteria, t — criteria of Student, single-factor analysis. It has been proven that patients with MI and AKI significantly higher rate of detected mutations in genetic variants such as G681A CYP2C19, C786T NOS3, Val174Ala SLCO1B1, associated with a worsening of the course of myocardial infarction in the hospital period obtained.
About the Authors
V. A. Siverina
Saint Petersburg I.I. Dzhanelidze research institute of emergency medicine
Russian Federation
Competing Interests: нет конфликта интересов
Russian Federation
Anna V. Siverina - cardiologist of Department of emergency cardiology and rheumаtology.
Budapeshtskaya, str. 3, Saint Petersburg, 192242
Competing Interests: нет конфликта интересов
E. A. Skorodumova
Saint Petersburg I.I. Dzhanelidze research institute of emergency medicine
Russian Federation
Competing Interests: нет конфликта интересов
Russian Federation
Elena A. Skorodumova MD., senior researcher Department of emergency cardiology and rheumаtology
Competing Interests: нет конфликта интересов
V. A. Kostenko
Saint Petersburg I.I. Dzhanelidze research institute of emergency medicine
Russian Federation
Competing Interests: нет конфликта интересов
Russian Federation
Viktor A. Kostenko - PhD, head of Department of emergency cardiology and rheumаtology
Competing Interests: нет конфликта интересов
L. P. Pivovarova
Saint Petersburg I.I. Dzhanelidze research institute of emergency medicine
Russian Federation
Competing Interests: нет конфликта интересов
Russian Federation
Lyudmila P. Pivovarova - MD, head of Department of laboratory diagnostics
Competing Interests: нет конфликта интересов
O. B. Ariskina
Saint Petersburg I.I. Dzhanelidze research institute of emergency medicine
Russian Federation
Competing Interests: нет конфликта интересов
Russian Federation
Olga B. Ariskina - PhD, researcher of Department of laboratory diagnostics
Competing Interests: нет конфликта интересов
A. N. Fedorov
Saint Petersburg I.I. Dzhanelidze research institute of emergency medicine
Russian Federation
Competing Interests: нет конфликта интересов
Russian Federation
Artyom N. Fedorov - cardiologist of Department of emergency cardiology and rheumаtology
Competing Interests: нет конфликта интересов
E. G. Skorodumova
Saint Petersburg I.I. Dzhanelidze research institute of emergency medicine
Russian Federation
Competing Interests: нет конфликта интересов
Russian Federation
Elizaveta G. Skorodumova - MSc, of Department of emergency cardiology and rheumаtology
Competing Interests: нет конфликта интересов
References
1. The Demographic Yearbook of Russia — 2014. Web page in Russian. [Демографический ежегодник России — 2014. Электронный ресурс]. URL: http://www.gks.ru/bgd/regl/B14_16/Main.htm (11 октября 2017).
2. Skorodumova EA, Kostenko VA, Ilyina VA, Siverina AV, Fedorov AN. Interference of background chronic kidney disease and acute tubular damage in patients with myocardial infarction. Translational Medicine = Translyatsionnaya meditsina. 2016; 3 (2): 40–45. In Russian [Скородумова Е.А., Костенко В.А., Ильина В.А., Сиверина А.В.,Фёдоров А.Н. Взаимовлияние фоновой хронической болезни почек и острого канальцевого повреждения у пациентов с инфарктом миокарда. Трансляционная медицина. 2016; 3 (2): 40–45].
3. Smirnov AV, Dobronravov VA, Rumyantsev ASh, Kayukov IG. Acute kidney injury. Moscow: Medical information Agency, 2015: 228–238. In Russian. [Смирнов А. В., Добронравов В. А., Румянцев А. Ш., Каюков И. Г. Острое повреждение почек. M.: Медицинское информационное агентство, 2015: 228–238].
4. Marenzi G, Gabiati A, Bertoli SV, et al. Incidence and relevance of acute kidney injury in patients hospitalized with acute coronary syndromes. Am.J.Cardiol. 2013; 20 (1): 816–822.
5. Roy AK, McGorrian C, Treacy C, et al. A Comparison of Traditional and Novel Definitions (RIFLE, AKIN, and KDIGO) of Acute Kidney Injury for the Prediction of Outcomes in Acute Decompensated Heart Failure. Cardiorenal Med. 2013; 3 (1): 26–37.
6. Abrahams E, Ginsburg GS, Silver M. The Personalized Medicine Coalition: goals and strategies. Am. J. Pharmacogenomics. 2005; 5: 345–355.
7. Bochkov NP, PuzyrevVP, Smirnyagina SA. Clinical genetics. Moscow: Geotar-Media, 2011. p. 592. In Russian [Бочков Н.П., Пузырёв В.П., Смирнихина С.А.. Клиническая генетика. М.: Гэотар-Медиа, 2011. с. 592].
8. Pchelina SN, Sirotkina OV, Sheidina AM, et al. Genetic Factors of Risk of Development of Myocardial Infarction in Young Men Living in North-West Region of Russia. Cardiolody = Kardiologiya. 2007; 7: 29–34. InRussian. [Пчелина С.Н., Сироткина О.В., Шейдина А.М. и др. Генетические факторы риска инфаркта миокарда у мужчин молодого возраста, проживающих в северо-западном регионе России. Кардиология. 2007; 7: 29–34].
9. Shesternya PA, Shulman VA, Nikulina SYu. Genetic aspects of myocardial infarction: problems and perspectives. Russian Journal Of Cardiology. 2012; 1 (93): 4–9. In Russian. [Шестерня П А, Шульман ВА, Никулина С Ю. Генетические аспекты инфаркта миокарда: проблемы и перспективы. Российский кардиологический журнал. 2012; 1 (93): 4–9].
10. Schunkert H, Erdmann J, Samani NJ. Genetics of myocardial infarction: a progress report. Eur. HeartJ. 2010; 31 (8): 918–925.
11. Postgenomic and nanotechnological innovations. ApoE (apolipoprotein E). Web page in Russian. [«ПИННИ» (Постгеномные и нанотехнологические инновации) ApoE (аполипопротеин Е). Электронный ресурс.] URL: http://пинни.рф/information/genes-information/132.html (11 октября 2017).
12. Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost. 2007; 5 (12): 2429-2436.
13. Zelenskaya EM, Slepuhina AA, Koch NV, et al. Genetic, pathophysiological and clinical aspects of antiplatelet therapy. Pharmacogenetics and Рharmacogenomics. 2015; 1:12-19. In Russian [Зеленская Е.М., Cлепухина А.А., Кох Н.В. и др.. Генетические, патофизиологические и клинические аспекты антиагрегантной терапии. Фармакогенетика и Фармакогеномика. 2015; 1: 12–19].
14. Mirzaev KB, Sychev DA, Karkischenko VN, et al. CYP2C19*2, CYP2C19*3, CYP2C19*17 allele and genotype frequencies in clopidogrel-treated patients with coronary heart disease from the Russian population. Biomedicine = Biomedistina. 2013; 1: 117–128. InRussian [Мирзаев К.Б., Сычёв Д.А., Каркищенко В.Н. и др. Частота полиморфных маркеров CYP2C19*2, CYP2C19*3, CYP2C19*17 среди русской популяции и сравнение распространенности CYP2C19*2 у пациентов с ишемической болезнью сердца, получающих терапию клопидогрелем, и здоровых добровольцев. Биомедицина. 2013;1: 117–128].
15. Komarov AL, Panchenko EP, Donnikov AE et al. Factors Determining Clinical Effectiveness of Clopidogrel and Prognosis of Patients With Stable Ischemic Heart Disease. Cardiology = Kardiologiya. 2011; 2: 8–18. In Russian. [Комаров А.Л., Панченко E.П., Донников А.Е. др. Факторы, определяющие клиническую эффективность клопидогрела и прогноз у больных со стабильной формой ишемической болезни сердца. Кардиология. 2011; 2: 8–18].
16. Sychev DA, Shuev GN, Prokofiev AB. Applied aspects of SLCO1B1 pharmacogenetic testing for predicting of statin-induced myopathy and personalization of statins therapy. Rational Pharmacotherapy in Cardiology. 2013;
17. (6): 698–700. In Russian. [Сычев Д.А., Шуев Г.Н., Прокофьев А.Б. Прикладные аспекты применения фармакогенетического тестирования по SLCO1B1 для прогнозирования развития статин индуцированной миопатии и персонализации применения статинов. Рациональная Фармакотерапия в Кардиологии. 2013; 9 (6): 698–700].
Review
For citations:
Siverina V.A., Skorodumova E.A., Kostenko V.A., Pivovarova L.P., Ariskina O.B., Fedorov A.N., Skorodumova E.G. GENETIC VARIANTS OF FUNCTIONING OF THE KEY PATHOGENETIC MECHANISMS IN PATIENTS WITH MYOCARDIAL INFARCTION AND ACUTE CARDIORENAL SYNDROME. Translational Medicine. 2017;4(6):6-12. (In Russ.) https://doi.org/10.18705/2311-4495-2017-4-6-6-12
Views:
846
Email this article 